It is notable that, after further subgrouping the patients who showed a significant HR for OS, this HR remained significant in ER + patients, but not in ER − patients (see ER + and ER − in Figure 6G), a finding in accordance with the results of the cell line based experiments.
A woman's age at breast cancer diagnosis was modeled as a random variable whose HR was, for noncarriers, exp(G) times the Australian breast cancer incidence rate for 1992-2002 [ 32] or, for carriers, the product of this HR multiplied by the age-specific HR.
The probable explanations for this HR-HPV peak in older Chinese women could be a cohort effect that leads to increased lifetime exposures, increased HPV incidence,and/or increased viral persistence in older women [ 33] versus younger women.
For each study, this HR was estimated by a method depending on the results provided in the original publication.
For each study, this HR was estimated by a method that depended on the results provided in the publication.
For each trial, this HR was estimated by a method depending on the data provided in the publications.
For each trial, this HR was estimated by a method that depended on the results provided in the publication.
We classified the patients into four subgroups for this purpose: HR-positive/HER-2-negative; HR-positive/HER-2-positive; HR-negative/HER-2-positive; and HR-negative/HER-2-negative cases.
After adjusting for being offered chemotherapy this HR was 1.43 (95% CI 0.57 3.60), a 66% reduction in excess risk of death.
